الفهرس 
General IntroductionOnly 14 pages are availabe for public view
 |  | from | 189 |  |  |
| | | from | 189 | | |
Abstract
This Study Aims To Formulate Relatively Safe Nanosystem Of Anticancer Agents, Doxorubicin (Dox) As A Model Drug And A Novel Quinazolinone Derivative (Qzo-Der) Loaded To Solid Lipid Nanoparticles (Slns) Using Carnauba Wax As A New Carrier To Release Anticancer Agents Directly To Colon Region By Low Doses To Accomplish The Same Therapeutic Effect Of Systemic Approach. A Box-Behnken Design Was Implemented To Investigate The Influence Of High Melting Point Wax Stabilized With Cell Membrane Lipid (Lecithin) And Non-Ionic Biocompatible Surfactant (Span 60) In Different Concentration On Particle Size, Entrapment Efficiency Of Each Drug And Percent Drug Release. Dox Slns And Qzo-Der Slns Were Produced By The Simple Hot Homogenization Method. The Slns Were Optimized By Design Expert Software, And characterized For Particle Size, Drug Entrapment, Differential Scanning Calorimetry (Dsc), Fourier Transform Infra-Red Spectroscopy (Ft-Ir), Transmission Electron Microscopy (Tem) And Drug Release Which Demonstrated Good Physical Stability With Small Particle Size. selected Formulations For Dox And Qzo-Der Were Generated After Validation Of Design. The In Vitro Anticancer Activity Was Tested Against Cancer Cell Lines Of Colorectal Cancer (Hct-116) Then Confirm The Activity Against Both Panel Of Wild Type And Dox-Resistant Human Cancer Cell Lines. Most Of The Tested Slns Improved The Efficacy Of Qzo-Der And Dox Against The Different Cancer Cell Lines And Have Extended The Spectrum To Cover Those Accruing Resistance During Chemotherapy. Delayed-Release Drug Delivery Capsules (Drddc) Were Prepared By Crosslinking Gelatin Of Capsule For Colon-Specific Delivery Which Capable Of Releasing Drug-Loaded Solid Nanoparticles In The Colorectal Region To Improve Chemotherapy For Crc. Complete Slns Release from Designated Delayed-Release Capsule Was Observed In-Vitro And In-Vivo In Rabbit Colon. This Study Presented The Potential Use Of Slns As An Efficient Carrier For Anticancer Drugs And Paves The Way For Further Studies On The Effectiveness Of These Slns In In-Vivo Cancer Animal Models.